Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma - results from the UK MRC OE02 trial

Matthew D. Hale, Matthew Nankivell, Gordon G. Hutchins, Sally P. Stenning, Ruth E. Langley, Wolfram Mueller, Nicholas P. West, Alexander I. Wright, Darren Treanor, Lindsay C. Hewitt, William H. Allum, David Cunningham, Jeremy D. Hayden, Heike I. Grabsch

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)77565-77575
Number of pages11
JournalOncotarget
Volume7
Issue number47
DOIs
Publication statusPublished - 22 Nov 2016

Keywords

  • biomarker
  • neoadjuvant chemotherapy
  • oesophageal cancer
  • proportion of tumour
  • tumour stroma

Cite this

Hale, M. D., Nankivell, M., Hutchins, G. G., Stenning, S. P., Langley, R. E., Mueller, W., West, N. P., Wright, A. I., Treanor, D., Hewitt, L. C., Allum, W. H., Cunningham, D., Hayden, J. D., & Grabsch, H. I. (2016). Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma - results from the UK MRC OE02 trial. Oncotarget, 7(47), 77565-77575. https://doi.org/10.18632/oncotarget.12723